CANCER JOURNAL is a leading peer-reviewed publication dedicated to the dissemination of innovative research in the fields of cancer research and oncology. Published by Lippincott Williams & Wilkins, this journal serves as an essential resource for researchers, clinicians, and students seeking to advance their understanding of cancer mechanisms, treatment strategies, and patient care. With an ISSN of 1528-9117 and an E-ISSN of 1540-336X, it boasts a respectable 2023 Q2 category ranking in both Cancer Research and Oncology, reflecting its impactful contributions to the scientific community. Although it currently does not offer open access, the journal's rigorous peer-review process ensures the publication of high-quality, relevant studies that stimulate further investigation and collaboration among professionals. Since its inception, the journal has evolved through several converged years, maintaining a steadfast commitment to addressing the complexities of cancer biology and treatment. At its core, CANCER JOURNAL aims to foster advancements in oncology, making it a vital platform for sharing pivotal findings that could transform cancer research and therapeutic practices.

The Journal of the National Comprehensive Cancer Network (ISSN: 1540-1405, E-ISSN: 1540-1413) is a premier publication in the field of oncology, established by HARBORSIDE PRESS and running since 2003. This highly respected journal holds a remarkable Q1 ranking in both Medicine (Miscellaneous) and Oncology categories, showcasing its significant influence and contribution to cancer research, with a Scopus ranking placing it within the top 5% of its field (Rank #20 out of 404). Aimed at a diverse audience including researchers, clinicians, and students, the journal publishes a wide range of articles that explore cutting-edge findings, clinical practices, and evidence-based guidelines in cancer care. With its commitment to advancing the understanding and treatment of cancer, it serves as a vital resource for professionals dedicated to improving patient outcomes. Although it does not currently offer open access, its impactful content continues to be a cornerstone for anyone involved in oncology research and practice.

Clinical and Experimental Hepatology is a pivotal journal dedicated to advancing the field of hepatology, providing a platform for researchers, clinicians, and students to disseminate and explore groundbreaking findings. Published by TERMEDIA PUBLISHING HOUSE LTD in Poland, this journal serves as a vital resource for professionals seeking to enhance their knowledge and contributions in the realm of liver diseases and their management. With an impact factor reflective of its growing influence—ranking Q3 in Hepatology for the year 2023 and holding the 49th position out of 82 in Scopus Medicine Hepatology ranks—this publication underscores the significance of innovative research in this specialized domain. While it currently operates through a subscription model rather than open access, it bridges the gap in hepatological literature by featuring a diverse array of scholarly articles, case reports, and reviews from 2015 to 2024. Researchers and health professionals alike will find valuable insights that can enhance clinical practice and inform future studies, solidifying its importance in the hepatology community.

Therapeutic Advances in Gastroenterology, published by SAGE Publications Ltd, is a premier open access journal dedicated to the advancement of knowledge in the field of gastroenterology. Since its inception in 2008 and its transition to open access in 2018, the journal has consistently provided high-quality peer-reviewed research articles, review papers, and clinical studies that address the latest therapeutic advancements and challenges in gastrointestinal medicine. With an impressive impact factor and a 2023 Scopus ranking placing it in the Q1 quartile of gastroenterology journals, it stands as a leading platform for researchers, clinicians, and healthcare professionals. The journal’s commitment to disseminating impactful research has positioned it at the forefront of academic discourse, offering a vital resource for those devoted to improving patient outcomes in digestive health. The United Kingdom-based journal invites submissions that contribute to the understanding and treatment of gastrointestinal disorders, ensuring that cutting-edge findings reach a global audience.

INTERNATIONAL JOURNAL OF HYPERTHERMIA, published by Taylor & Francis Ltd, is a leading peer-reviewed journal dedicated to advancing the field of hyperthermia and its applications in medical science, particularly within cancer research and related disciplines. With an ISSN of 0265-6736 and an E-ISSN of 1464-5157, this journal has been a vital resource since its establishment in 1985, offering a platform for innovative research and clinical applications aimed at improving treatment outcomes. The journal is recognized with a Q2 category ranking in several fields, including Cancer Research and Physiological Medicine, reflecting its significant contribution to scientific knowledge and clinical practices. Furthermore, it has been Open Access since 2019, ensuring that cutting-edge research is accessible to a global audience. By facilitating the exchange of ideas and fostering collaborations among researchers, professionals, and students, the INTERNATIONAL JOURNAL OF HYPERTHERMIA serves as an essential resource in the quest to exploit hyperthermia’s full potential in therapeutic settings.

Hepatology Research, ISSN 1386-6346 and E-ISSN 1872-034X, is a premier academic journal published by Wiley that serves the dynamic fields of Hepatology and Infectious Diseases. With an impressive 2023 impact factor and ranked Q2 in Hepatology and Q1 in Infectious Diseases, this journal stands out as a vital resource for researchers, professionals, and students. Covering a broad spectrum of topics related to liver health, the journal aims to disseminate cutting-edge research and insights from the converged years of 1997 to 2024. As an open-access platform, it fosters the global sharing of knowledge, providing valuable access to pioneering studies that address pressing issues in liver disease and its associated infections. Based in the United Kingdom, at 111 River St, Hoboken, NJ, Hepatology Research is pivotal for advancing scientific understanding and improving patient outcomes worldwide.

Clinical Gastroenterology and Hepatology, published by Elsevier Science Inc, stands as a leading journal in the fields of gastroenterology and hepatology. With an ISSN of 1542-3565 and an E-ISSN of 1542-7714, this esteemed publication has earned its place in the top quartile (Q1) of both gastroenterology and hepatology categories as of 2023, ranking 6th out of 167 and 7th out of 82 respectively. The journal aims to disseminate innovative research, clinical studies, and case reports that advance the understanding and treatment of gastrointestinal and liver diseases. Targeted towards researchers, healthcare professionals, and students, it provides crucial insights into emerging therapies and medical advancements. Clinical Gastroenterology and Hepatology is not only a pivotal resource for contemporary gastroenterological research but also fosters collaboration and knowledge-sharing within the medical community. With a converging publication history from 2003 to the present, the journal continues to build on its solid foundation of scientific excellence and relevance.

Canadian Journal of Gastroenterology and Hepatology, published by HINDAWI LTD, serves as a vital resource in the fields of gastroenterology and hepatology. Since its inception in 1987, this open-access journal has made significant contributions to advancing research and clinical practice through its comprehensive coverage of topics ranging from liver diseases to gastrointestinal disorders. With an impressive Q2 ranking in Gastroenterology and a Q3 ranking in Hepatology as of 2023, the journal has established itself as an influential platform for researchers and healthcare professionals seeking to disseminate and acquire knowledge. The journal is based in Egypt, with its operational headquarters located in London, England. Notably, it holds a respectable standing in Scopus rankings, placed at Rank #64 in Gastroenterology and Rank #34 in Hepatology, reflecting its impact and relevance in the medical community. With a commitment to quality and accessibility, the Canadian Journal of Gastroenterology and Hepatology continues to foster innovation and collaboration among its readers.

Hepatic Medicine-Evidence and Research is a distinguished open-access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing knowledge in the field of hepatology. Since its inception in 2009, this journal has served as a critical platform for researchers, professionals, and students alike, facilitating the dissemination of high-quality, peer-reviewed articles that address the latest developments in hepatic medicine. With a commitment to accessibility, all articles are freely available to a global audience, thereby promoting collaboration and innovation in research. Although specific metrics such as H-index and Scopus ranks are currently undeclared, the journal is recognized for its contributions to clinical practice and ongoing research in liver health, making it an essential resource for those seeking to enhance their understanding of hepatic conditions and treatments. By prioritizing the latest evidence and research in this vital field, Hepatic Medicine-Evidence and Research continues to play a pivotal role in influencing clinical outcomes and shaping future studies.

Future Oncology is a premier peer-reviewed journal published by FUTURE MEDICINE LTD, dedicated to advancing research and innovation within the field of oncology. Established in 2005 and set to continue through 2024, this journal serves as an essential resource for researchers, healthcare professionals, and students engaged in cancer studies. With its emphasis on groundbreaking findings and multidisciplinary approaches, Future Oncology holds an esteemed reputation, reflected in its 2023 category quartiles ranking it in Q2 for Cancer Research and Q1 for Medicine (miscellaneous). The journal is indexed in Scopus, showcasing its rigorous content, with rankings in the 63rd percentile for Oncology and the 46th percentile for Cancer Research. Although it does not operate on an open-access model, its commitment to disseminating cutting-edge findings makes it an invaluable asset for those seeking to stay at the forefront of oncology research.Future Oncology strives to bridge the gap between laboratory and clinical research, fostering collaboration and appreciation for the complexities of cancer treatment.